RAIN

Rain Therapeutics Inc. [RAIN] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

RAIN Stock Summary

Top 10 Correlated ETFs

RAIN

Top 10 Correlated Stocks

RAIN

In the News

RAIN Financial details

Company Rating
-
Market Cap
44.01M
Income
-71M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
63
Optionable
No
Shortable
Yes
Earnings
07 Mar 2024
P/E
-0.61
Forward P/E
-
PEG
0.26
P/S
-
P/B
0.65
P/C
-
P/FCF
-0.64
Quick Ratio
5.38
Current Ratio
5.58
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.03
EPS next Y
-
EPS next Q
-
EPS this Y
2.26%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-68.85%
-
-
-
-
SMA20
-28.54%
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-87%
ROE
-82%
ROC
-1.13%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.82-11.32
52W High
-
52W Low
-
RSI
23.14
Rel Volume
0.06
Avg Volume
238.29K
Volume
13.76K
Perf Week
-19.76%
Perf Month
-47.09%
Perf Quarter
-
Perf Half Y
-63.84%
-
-
-
-
Beta
0.273
-
-
Volatility
0.29%, 0.65%
Prev Close
-0.75%
Price
2.64
Change
-2.58%

Something similar

Top by Market Cap
VTSAX
DHR-PB
1YD.DE
0YXG.L
APC.DE
Top Correlated ETFs
YXI
YANG
EDZ
EEV
EUM
Top Correlated Stocks
ZBRA
RSLS
SLRX
RELI
HBI
Similar Market Cap
FXA
ISO
PLBY
EOPS
NUBC

Company Profile

Healthcare Biotechnology
  • Volume Average 238.29K
  • Market Capitalization 44.01M
  • Employee 63
  • CEO Mr. Avanish Vellanki M.B.A.
  • Headquarters Newark,CA,US
  • IPO Date 2021-04-23
  • Website https://www.rainthera.com

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.